Table III.
Summary of T cell responses of patients completing APC/Gal therapy
| Baseline | Day 49 | Day 70 | |
|---|---|---|---|
| CD4 Ta | 16.3 ± 1.3 | 17.4 ± 1.1 | 17.2 ± 1.2 |
| Tn CD4 Tb | 51.3 ± 3.2 | 49.3 ± 3.3 | 50.9 ± 3.0 |
| TEM/TE CD4 Tb | 24.5 ± 2.3 | 26.7 ± 2.8 | 24.5 ± 2.5 |
| TCM CD4 Tb | 20.4 ± 1.5 | 20.7 ± 1.4 | 20.5 ± 1.4 |
| Regulatory T cellsb | 0.7 ± 0.2 | 0.6 ± 0.1 | 0.6 ± 0.2 |
| CD8 Ta | 8.6 ± 0.9 | 9.6 ± 1.0 | 10.5 ± 1.1 |
| Tn CD8 Tc | 30.0 ± 4.2 | 30.5 ± 4.6 | 25.8 ± 4.0 |
| TEM/TE CD8 Tc | 26.6 ± 2.9 | 29.6 ± 3.4 | 30.1 ± 3.5 |
| TCM CD8 Tc | 3.7 ± 0.6 | 3.8 ± 0.7 | 3.3 ± 0.4 |
| CMV-reactive CD8 Tc | 0.3 ± 0.1 | n.d. | 0.2 ± 0.1 |
| cDCd | 63.7 ± 3.0 | 59.0 ± 3.7 | 61.7 ± 3.2 |
| pDCd | 18.1 ± 1.6 | 18.2 ± 2.0 | 21.0 ± 2.0 |
| MDSCa | 3.5 ± 0.5 | 2.8 ± 0.3 | 2.3 ± 0.2 |
CMV-specific CD8+ T cells were detected by HLA-A2+ or HLA-A24+ tetramer. n.d., not done; cDC, conventional DC; pDC, plasmacytoid DC; TCM, central memory T (CD45RA−CCR7+); TEM/EF, effector memory/effector T (CD45RA−CCR7−); Tn, naive T (CD45RA+CCR7+).
a
Percentage in leukocytes.
b
Percentage in CD4 T cells.
c
Percentage in CD8 T cells.
d
Percentage in lineage−HLA-DR+ leukocytes.